Literature DB >> 15350035

Embolization of sacral tumors.

Oren N Gottfried1, Meic H Schmidt, Edwin A Stevens.   

Abstract

The management of sacral tumors is challenging because of difficulties in accessing the lesion, the high rate of local recurrence, extensive vascularity causing significant intraoperative blood loss, resistance to radiation therapy, and risk of malignant transformation. Although surgery is the main treatment for many sacral tumors, embolization is a valuable primary and adjunctive therapy. Patients with benign lesions, including aneurysmal bone cysts and giant cell tumors, have responded to embolization with resolution of their symptoms and with ossification of their lesions. Embolization is used as a primary therapy for metastatic lesions and results in neurological improvement, reduced tumor size, and decreased spinal canal compromise. It is also used as an adjuvant therapy to reduce intraoperative blood loss and to aid in the resection of benign, malignant, and metastatic sacral lesions. It is important to note that embolization techniques are a valuable resource in the treatment of sacral tumors, and, overall, embolization should always be considered in patients with sacral tumors.

Entities:  

Mesh:

Year:  2003        PMID: 15350035     DOI: 10.3171/foc.2003.15.2.4

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  16 in total

Review 1.  Paediatric musculoskeletal interventional radiology.

Authors:  Gian L Natali; Guglielmo Paolantonio; Rodolfo Fruhwirth; Giuseppe Alvaro; George K Parapatt; Paolo Toma'; Massimo Rollo
Journal:  Br J Radiol       Date:  2015-09-23       Impact factor: 3.039

2.  Complications after selective embolization in the bilateral internal iliac arteries and the median sacral artery with gelfoam particles in dogs.

Authors:  Yetian Li; Wei Wang; Guangye Wang; Zongsheng Yin
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor.

Authors:  Pietro Ruggieri; Andreas F Mavrogenis; Giuseppe Ussia; Andrea Angelini; Panayiotis J Papagelopoulos; Mario Mercuri
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

4.  Giant sacral schwannomas.

Authors:  Sedat Çağlı; Hasan Serdar Işık; Umut Yıldırım; Nevhis Akıntürk; Mehmet Zileli
Journal:  J Neurooncol       Date:  2012-07-18       Impact factor: 4.130

Review 5.  Metastatic bone disease from breast cancer: a review of minimally invasive techniques for diagnosis and treatment.

Authors:  Dimitrios Filippiadis; Andreas F Mavrogenis; Argyro Mazioti; Konstantinos Palialexis; Panayiotis D Megaloikonomos; Panayiotis J Papagelopoulos; Alexis Kelekis
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-06-08

6.  Selective arterial embolisation for bone tumours: experience of 454 cases.

Authors:  G Rossi; A F Mavrogenis; E Rimondi; F Ciccarese; C Tranfaglia; B Angelelli; G Fiorentini; T Bartalena; C Errani; P Ruggieri; M Mercuri
Journal:  Radiol Med       Date:  2011-03-19       Impact factor: 3.469

7.  Giant cell tumor of the sacrum treated with selective arterial embolization.

Authors:  Hitoshi Onishi; Mitsunori Kaya; Takuro Wada; Satoshi Nagoya; Mikito Sasaki; Toshihiko Yamashita
Journal:  Int J Clin Oncol       Date:  2010-03-04       Impact factor: 3.402

8.  Percutaneous treatment of a sacral metastasis with combined embolization, cryoablation, alcohol ablation and sacroplasty for local tumor and pain control.

Authors:  J H Lee; M Stein; S Roychowdhury
Journal:  Interv Neuroradiol       Date:  2013-05-21       Impact factor: 1.610

9.  Does point of care prothrombin time measurement reduce the transfusion of fresh frozen plasma in patients undergoing major surgery? The POC-OP randomized-controlled trial.

Authors:  Natalie Urwyler; Sven Trelle; Lorenz Theiler; Peter Jüni; Lukas P Staub; Cedric Luyet; Lorenzo Alberio; Kay Stricker; Robert Greif
Journal:  Trials       Date:  2009-11-23       Impact factor: 2.279

10.  Surgical Treatment of Sacral Metastatic Tumors.

Authors:  Mengxiong Sun; Dongqing Zuo; Hongsheng Wang; Jiakang Sheng; Xiaojun Ma; Chongren Wang; Pengfei Zan; Yingqi Hua; Wei Sun; Zhengdong Cai
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.